ANNUAL SYMPOSIUM
Scientific Update in Breast Cancer:
Detection, Preclinical Modeling and Therapeutic Targeting

Friday, April 25, 2014
Philadelphia, Pennsylvania

An All-Day Scientific and Clinical Symposium
Course Description

Breast cancer is one of the leading causes of cancer-related mortality in women both in the U.S. and worldwide. However, there have been dramatic advances in our understanding of the benefits of careful screening of high-risk individuals, the molecular biology of breast cancer, novel targets of importance, and the development of targeted therapies.

The latest advances in both breast cancer treatment and research—including innovations in molecular diagnostics, surgical management, systemic therapy and loco-regional radiation approaches—will be discussed Friday, April 25, 2014, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

The all-day, breast cancer symposium, part of an annual series at the Kimmel Cancer Center, will be held at the Bluemle Life Sciences Building, 233 S. 10th Street, beginning at 8:30 a.m.

“This symposium is an opportunity for those players to come together and highlight the innovative discoveries we believe will be important for the next generation of therapeutics in breast cancer patients and to demonstrate how Jefferson plays a leading role in implementing these transformative approaches,” adds Dr. Massimo Cristofanilli, Director of the Jefferson Breast Care Center. A range of topics will be covered by top experts here at Jefferson and other institutions in the United States.

Learning Objectives

At the conclusion of this course, participants should be able to:

- Apply updated guidelines in screening for breast cancer
- Integrate new diagnostic options into their practices
- Integrate new treatment options into their practices
- Integrate new imaging modalities into their practices
- Apply updated guidelines in screening for breast cancer

Target Audience

Pathologists, Surgeons, Radiation Oncologists, and Medical Oncologists, and all other healthcare professionals involved in the study and the decision making process about breast cancer patients’ treatment and care.

Accreditation

Jefferson Medical College of Thomas Jefferson University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Jefferson Medical College of Thomas Jefferson University designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Society of Clinical Research Associates (SoCRA) accepts documentation of candidate participation in continuing education programs for re-certification if the clinical program is applicable to clinical research regulations, operations or management, or to the candidate’s clinical research therapeutic area.

Course Directors

Richard G. Pestell, MD, PhD, MB, BS, MBA, FACP, FRACP
Professor and Chair
Department of Cancer Biology
Jefferson Medical College
Director
Kimmel Cancer Center
Conference Chair

Massimo Cristofanilli, MD, FACP
Professor
Department of Medical Oncology
Jefferson Medical College
Director
Jefferson Breast Care Center
Deputy Director
Translational Research
Director
Siddi Tumor Breast Program
Conference Co-Chair

Hallgeir Rui, MD, PhD
Professor
Department of Cancer Biology
Medical Oncology, and Pathology
Scientific Director
Jefferson Breast Care Center
Leader
Biology of Breast Cancer Program
Kimmel Cancer Center
Jefferson Medical College
Conference Co-Chair

Theodore Tsangaris, MD, FACＳ
Professor
Department of Surgery
Surgical Director
Jefferson Breast Care Center
Chief
Breast Surgery
Jefferson Medical College
Conference Co-Chair

Faculty Members

P. Rani Anné, MD
Associate Professor
Department of Radiation Oncology
Jefferson Medical College

Tiffany Avery, MD
Associate Professor
Department of Medical Oncology
Jefferson Medical College

Andrea Barsevick, PhD, RN
Associate Professor
Division, Population Science
Department of Medical Oncology
Jefferson Medical College

Jenny C. Chang, MD
Professor
Department of Medicine
Medical Director
Lester and Sue Smith Breast Center
Baylor College of Medicine

Alessandro Fatatis, MD, PhD
Professor
Departments of Pharmacology & Physiology
and Pathology and Laboratory Medicine
Drexel University College of Medicine

Ann C. Klassen, PhD
Professor and Chair
Department of Community Health and Prevention
Associate Dean for Research
Public Health
Drexel University College of Medicine

Edith P. Mitchell, MD, FACP
Professor and Chair
Department of Pathology and Laboratory Medicine
MD Anderson Cancer Center

Juan P. Palazzo, MD
Professor
Department of Pathology, Anatomy and Cell Biology
Jefferson Medical College

W. Fraser Symmans, MD
Professor
Department of Pathology
Director
Research Operations
Department of Pathology
The University of Texas
MD Anderson Cancer Center

Madhukar (Mathew) L. Thakur, MD
Professor
Department of Radiology
Director
Radiopharmaceutical & Nuclear Medicine Research
Jefferson Medical College

Wendy A. Woodward, MD, PhD
Associate Professor
Department of Radiation Oncology
Service Chief
Breast Cancer Radiation Oncology Program
The University of Texas
MD Anderson Cancer Center

Hushan Yang, PhD
Assistant Professor
Division, Population Science
Department of Medical Oncology
Jefferson Medical College
Scientific Update in Breast Cancer:
Detection, Preclinical Modeling and Therapeutic Targeting

8:30 a.m. – 8:35 a.m.  Welcoming Remarks
Richard G. Pestell, MD, PhD, MB, BS, MBA, FACP, FRACP
Professor and Chair, Cancer Biology, Director, Kimmel Cancer Center at Jefferson
Massimo Cristofanilli, MD, FACP
Professor of Medical Oncology, Director, Jefferson Breast Care Center
Deputy Director, Translational Research, Director, Solid Tumor Breast Program

8:35 a.m. – 9:10 a.m.  Keynote Address
The Heterogeneity of TNBC in the Molecular Era
W. Fraser Symmans, MD

9:10 a.m. – 9:30 a.m.  Keynote Address
Is There is Still a Role for Standard Histology in Breast Cancer Diagnostics?
Juan P. Palazzo, MD

9:30 a.m. – 9:50 a.m.  Molecular Diagnostics in Breast Cancer: Analyzing the Tissue, the Blood or Both?
Massimo Cristofanilli, MD, FACP

9:50 a.m. – 10:00 a.m.  Discussion

10:00 a.m. – 10:20 a.m.  Coffee Break

10:20 a.m. – 10:50 a.m.  Preclinical Models and Novel Molecular Therapies in Breast Cancer
Co-Chairs: Hallgeir Rui, MD, PhD, and Massimo Cristofanilli, MD, FACP

10:20 a.m. – 10:50 a.m.  Keynote Address
Characterization and Targeting of Cancer Stem Cells
Jenny C. Chang, MD

10:50 a.m. – 11:10 a.m.  Patient-derived Breast Cancer Xenograft Models in Prolactin-humanized Mice
Hallgeir Rui, MD, PhD

11:10 a.m. – 11:30 a.m.  Novel Antagonists of CX3CR1 Impair the Homing of Breast Cancer Cells to the Skeleton
Alessandro Fatatis, MD, PhD

11:30 a.m. – 11:50 a.m.  CCR5 Inhibitors of Metastasis
Richard G. Pestell, MD, PhD, MBBS, FRACP, MBA

11:50 a.m. – 12:10 a.m.  Adaptive PARP-Inhibitor Trial
Tiffany Avery, MD

12:10 a.m. – 12:20 p.m.  Discussion

12:20 p.m. – 1:20 p.m.  Lunch Break and Poster Session

Integration of Molecular Diagnostic Technologies in the Management of Breast Cancer
Co-Chairs: Juan P. Palazzo, MD, and Paolo M. Fortina, MD, PhD

12:10 p.m. – 1:20 p.m.  Imaging Modalities and Loco-regional Therapies for Primary Breast Cancer
Co-Chairs: Theodore Tsangaris, MD, FACS, and Rani P. Anne, MD

12:10 p.m. – 1:20 p.m.  Keynote Address
Radiotherapy and Local Control in IBC
Wendy A. Woodward, MD, PhD

1:20 p.m. – 1:50 p.m.  Molecular Imaging
Madhukar (Mathew) L. Thakur, PhD

1:50 p.m. – 2:10 p.m.  Evolving Role of Surgical Management of the Axilla in PBC
Theodore Tsangaris, MD, FACS

2:10 p.m. – 2:30 p.m.  Discussion

2:30 p.m. – 2:40 p.m.  Break

2:40 p.m. – 3:10 p.m.  Evolving Concepts in Epidemiology, Risk Assessment and Prevention of Breast Cancer
Co-Chairs: Andrea Barsevick, PhD, RN, and Edith P. Mitchell, MD, FACP

2:40 p.m. – 3:10 p.m.  Outreach and Minorities
Edith P. Mitchell, MD, FACP

3:10 p.m. – 3:30 p.m.  Epidemiology
Ann C. Klassen, PhD

3:30 p.m. – 3:50 p.m.  Caloric Restriction Trial
Nicole Simone, MD

3:50 p.m. – 4:10 p.m.  Is There a Role for Molecular Risk Assessment in Breast Cancer?
Hushan Yang, PhD

4:10 p.m. – 4:20 p.m.  Discussion

4:20 p.m. – 4:30 p.m.  Closing remarks

During the live symposium, follow us on Twitter at #KCCbreast14

Continental breakfast, breaks and lunch will be provided.
About the Kimmel Cancer Center at Jefferson

The Kimmel Cancer Center (KCC) was founded in 1991 with approximately 30 investigators in the basic sciences. Today, the KCC has approximately 150 members that include physicians and scientists dedicated to discovery and development of novel approaches for cancer treatment. The mission of the Kimmel Cancer Center, a National Cancer Institute-designated Cancer Center, is:

- to make transformational discoveries of the cellular and molecular biology of the malignant process and the individual's and society's response to it
- to effectively translate the latest research discoveries into clinical trials to provide the highest quality of care to all patients including those of diverse ethnic and racial populations
- to provide expert and humanitarian care to cancer patients, their families, and those at risk

U.S. News & World Report recognizes Jefferson as one of the best hospitals in the nation for Cancer care. Jefferson is also a Blue Distinction Center for Complex and Rare Cancers. Blue Distinction is a nationwide program of the Blue Cross and Blue Shield Association, recognizing specialty centers that offer the best practices and standards of cancer care.

The Kimmel Cancer Center is proud of its status as a National Cancer Institute-designated Cancer Center. The NCI-designated cancer centers were established to provide expert and humanitarian care to cancer patients, their families, and those at risk. The National Cancer Institute oversees the NCI's programs and policies, must recommend approval for a center to receive the comprehensive designation. The center must repeat an external review of the steps above every three to five years.

About the Jefferson Kimmel Cancer Center Network

In 1993, the Jefferson Kimmel Cancer Center Network was established to provide patients in its member hospitals access to the latest developments in cancer research, technology and treatment. Jefferson’s Kimmel Cancer Center offers patients at member hospitals the opportunity to participate in clinical trials utilizing state-of-the-science approaches to preventing, diagnosing and treating cancer. Physicians in the network take advantage of each other’s consultative knowledge, and patients have a greater opportunity to benefit from innovative treatment options close to home.

Network Members

- Aria Health
- Alfred I. duPont Institute for Children
- Einstein Medical Center Philadelphia
- Ephraim Community Hospital
- Hem & Onc Associates of NE PA PC
- Hudson Valley Oncology Associates
- Inspira Medical Center Woodbury
- Jefferson Hospital for Neuroscience
- Jefferson Health
- Jennesville Regional Hospital
- Kimmel Cancer Center at Jefferson
- Mercy Fitzgerald Hospital
- Mercy Hospital Philadelphia
- Mercy Suburban Hospital
- Methodist Hospital
- Nazareth Hospital
- Northeast Radiation Oncology Center
- Pocono Medical Center
- Reading Hospital
- Riddle Hospital
- St. Francis Cancer Center
- St. Francis Hospital (Wilmingt)
- Sacred Heart Hospital
- Sparta Cancer Center
- Trinitas Regional Medical Center
- Upper Delaware Valley Cancer Center
- Wills Eye Institute
- Male
- Female
- Web ID: Please provide the last four digits of your Social Security Number as your Web ID. This will allow you to access your CME transcript at any time after the course.
- Registration Deadline is April 18, 2014

About the Jefferson Kimmel Cancer Center Consortium

In May 2012, Drexel University (DU) and Thomas Jefferson University (TJU) established an overarching General Research Affiliation Agreement and a specific Cancer Research Affiliation Agreement to form a cancer research consortium with the Kimmel Cancer Center (KCC) at TJU. Lankenau Institute for Medical Research (LIRM) is also a formal consortium member of the KCC. As part of the Consortium, all faculty and students from both institutions are welcome to participate in seminars and networking activities.